Safety and efficacy of eltrombopag (EPAG) vs placebo (PBO) for treatment of chemotherapy (CTx)-induced thrombocytopenia (TCP) in patients (Pts) with solid tumors receiving gemcitabine (GEM)-based CTx: A phase 2 study.
Eric S. Winer(Providence College), Yasser Mostafa Kamel(Daiichi Sankyo (United States)), Denise C. Althouse(GlaxoSmithKline (United States)), Brendan M. Johnson(Research Triangle Park Foundation), Geoffrey Chan(GlaxoSmithKline (United States)), Bogusława Karaszewska(State University of Applied Sciences in Konin), Paul Burgess(Princess Alexandra Hospital), Frédéric Forget, Howard Safran(Brown University), Dilawar Khan(Harbin Clinic), Sebastian Bauer(Science for Life Laboratory)
Cited by 2
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k